AbbVie has acquired global rights to the lead pipeline asset of Ichnos Glenmark Innovation (IGI), the cancer and autoimmune disease candidate ISB 2001, now in development against multiple myeloma, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback